Last reviewed · How we verify
NCT07507539: MET-CMP
Metabolomic Profiling in Ischemic and Non-Ischemic Cardiomyopathy Patients With Ventricular Arrhythmias
trial in Heart Failure With Reduced Ejection Fraction (HFrEF) in 60 participants. Completed in 25 March 2026.
25 March 2026
Quick facts
| Lead sponsor | Muhammed Heja Geçit |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 2 March 2025 |
| Primary completion | 25 March 2026 |
| Estimated completion | 25 March 2026 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Heart Failure With Reduced Ejection Fraction (HFrEF) — all drugs for Heart Failure With Reduced Ejection Fraction (HFrEF) →
- Ventricular Tachycardia (VT) — all drugs for Ventricular Tachycardia (VT) →
- Ischemic Cardiomyopathy — all drugs for Ischemic Cardiomyopathy →
- Non-ischemic Cardiomyopathy — all drugs for Non-ischemic Cardiomyopathy →
Sponsor
Muhammed Heja Geçit
Who can join
18 and older, any sex, with Heart Failure With Reduced Ejection Fraction (HFrEF) or Ventricular Tachycardia (VT). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This single-center prospective observational study aims to evaluate differences in metabolomic pathways between patients with ischemic and non-ischemic cardiomyopathy with reduced left ventricular ejection fraction and documented ventricular tachycardia. Patients followed at Istanbul University-Cerrahpasa Cardiology Institute Hospital will be included if they meet predefined eligibility criteria. Participants will be categorized into two cohorts according to the etiology of cardiomyopathy: ischemic and non-ischemic. Biospecimens will be collected for metabolomic analyses to identify alterations in metabolic pathways and individual metabolites. The study also aims to explore associations between metabolomic profiles and clinical characteristics, including arrhythmia burden and cardiac function parameters. The findings may provide insights into the underlying pathophysiological mechanisms of ventricular arrhythmias in heart failure and contribute to improved risk stratification and personalized management strategies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07507539
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure With Reduced Ejection Fraction (HFrEF)
Currently open trials in the same condition.
- NCT07518030 — Telemedicine-guided Uptitration of Therapy in Chronic Heart Failure · NA · recruiting
- NCT07405944 — Vericiguat and Reverse Remodeling Indices in Heart Failure · Phase 4 · recruiting
- NCT06964464 — Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardio · Phase 4 · recruiting
- NCT06909682 — AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices · recruiting
- NCT07259512 — Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fra · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07507539 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Muhammed Heja Geçit
- Last refreshed: 2 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07507539.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing